These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

758 related items for PubMed ID: 1826536

  • 1. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD.
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [Abstract] [Full Text] [Related]

  • 2. [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
    Tanosaki R, Okamoto S, Takahashi S, Inoue T, Kikuno K, Aoki Y, Takada M, Irie S, Shimane M, Tojo A.
    Rinsho Ketsueki; 1993 Aug; 34(8):946-51. PubMed ID: 8105115
    [Abstract] [Full Text] [Related]

  • 3. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W.
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
    Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L.
    Blood; 1991 Feb 15; 77(4):700-11. PubMed ID: 1993213
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B, Hiddemann W, Frisch J, Zühlsdorf M, Rottmann R, Boeckmann A, Reuter C, Freire EA, Innig G, Schulz G.
    Behring Inst Mitt; 1991 Dec 15; (90):28-38. PubMed ID: 1801688
    [Abstract] [Full Text] [Related]

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi HA, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS.
    Leukemia; 2002 Mar 15; 16(3):310-5. PubMed ID: 11896533
    [Abstract] [Full Text] [Related]

  • 7. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
    Bernell P, Kimby E, Hast R.
    Leukemia; 1994 Oct 15; 8(10):1631-9. PubMed ID: 7934158
    [Abstract] [Full Text] [Related]

  • 8. Influence of rhGM-CSF on Ara-C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study.
    Lacombe F, Puntous M, Dumain P, Cony-Makhoul P, Belloc F, Bernard P, Boisseau M, Reiffers J.
    Leuk Res; 1996 Jun 15; 20(6):481-9. PubMed ID: 8709620
    [Abstract] [Full Text] [Related]

  • 9. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
    Cannistra SA, Groshek P, Griffin JD.
    Leukemia; 1989 May 15; 3(5):328-34. PubMed ID: 2654494
    [Abstract] [Full Text] [Related]

  • 10. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU.
    Exp Hematol; 1992 Jun 15; 20(5):558-64. PubMed ID: 1587302
    [Abstract] [Full Text] [Related]

  • 11. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
    te Boekhorst PA, Löwenberg B, Sonneveld P.
    Leukemia; 1994 Sep 15; 8(9):1480-6. PubMed ID: 7522289
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R, Hohaus S, Egerer G, Ehrhardt R, Witt B, Hunstein W.
    Bone Marrow Transplant; 1992 Jun 15; 9(6):459-65. PubMed ID: 1352717
    [Abstract] [Full Text] [Related]

  • 13. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction.
    Lanza F, Rigolin GM, Castagnari B, Moretti S, Castoldi G.
    Haematologica; 1997 Jun 15; 82(2):239-45. PubMed ID: 9175331
    [Abstract] [Full Text] [Related]

  • 14. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 15. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suciu S, Dardenne M, Solbu G, de Witte T, Jacobs A, Visani G.
    Leukemia; 1994 Jan 15; 8(1):16-23. PubMed ID: 8289481
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, Bonnem E, Burgess AW, McGrath K, Fox RM.
    Cancer Res; 1990 Feb 01; 50(3):606-14. PubMed ID: 2404573
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 01; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 18. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
    Yang GS, Minden MD, McCulloch EA.
    Leukemia; 1993 Jul 01; 7(7):1012-9. PubMed ID: 7686602
    [Abstract] [Full Text] [Related]

  • 19. Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
    Wörmann B, Reuter C, Zühlsdorf M, Büchner T, Hiddemann W.
    Semin Oncol; 1994 Dec 01; 21(6 Suppl 16):39-43. PubMed ID: 7801145
    [Abstract] [Full Text] [Related]

  • 20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 01; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.